Compare SNFCA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | NTHI |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1M | 195.5M |
| IPO Year | N/A | N/A |
| Metric | SNFCA | NTHI |
|---|---|---|
| Price | $8.60 | $9.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.7K | ★ 74.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $340,876,482.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | ★ 3.25 | N/A |
| 52 Week Low | $7.32 | $3.20 |
| 52 Week High | $12.94 | $25.00 |
| Indicator | SNFCA | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 50.88 |
| Support Level | $7.76 | $5.58 |
| Resistance Level | $8.74 | $9.45 |
| Average True Range (ATR) | 0.28 | 1.25 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 88.46 | 53.74 |
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).